| Literature DB >> 28794865 |
Abstract
Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the PML-RARA fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.Entities:
Keywords: PML; RARA; leukemia
Year: 2017 PMID: 28794865 PMCID: PMC5538034 DOI: 10.12688/f1000research.10736.1
Source DB: PubMed Journal: F1000Res ISSN: 2046-1402